Scientists at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) have identified a promising drug candidate for the treatment of multi-inflammatory syndrome in children (MIS-C), they report in Clinical Care Explorations. MIS-C is a rare but severe and potentially life-threatening condition that usually develops in children weeks to months after they have experienced a mild or even asymptomatic case of COVID-19.
MIS-C occurs mainly in children and leads to high fevers and a hyperinflammatory response that can affect multiple organs, including the heart, brain and gastrointestinal organs. Symptoms include stomach pain, diarrhea, vomiting, dizziness and rash. Fifty-five of the 6,431 children diagnosed with MIS-C have died since May 2020, according to the Centers for Disease Control and Prevention… Continue reading.
Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study led by investigators at Dana-Farber Cancer Institute reports. The study, published online by the journal Blood Advances, found that patients who had received anti-CD20 antibody therapy within the previous 12 months did not develop protective antibodies for COVID-19 after being vaccinated.
“Our findings suggest that patients with lymphoid cancers who have been vaccinated for COVID-19 should not assume they have immunity against the disease… Continue reading.
COVID-19 antibody tests have been the subject of scrutiny since their arrival, but they still represent an important tool in understanding population health. Molecular tests have become the top method of identifying cases of COVID-19. One scientist thinks we should be looking at using a combination of antibody tests, antigen tests, and molecular RNA tests to better understand who has COVID-19 and whether or not they’re actively recovering.
Dr. David Walt is one of the cofounders of genetic sequencing technology giant Illumina and Quanterix, a company that makes technology for detecting biomarkers. He is also co-director of the MGB Center for COVID Innovation at Brigham and Women’s Hospital, in Boston. When COVID-19 struck, he had to close his lab at Harvard University due to the pandemic. He petitioned to reopen, so he and a team could work on a super antibody test that would enable him to better understand immune response in COVID-19 patients. The request was approved… Continue reading.